Your browser doesn't support javascript.
loading
Discovery of pyrano[2,3-d]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity.
Abd El-Sattar, Nour E A; Badawy, Eman H K; Elrazaz, Eman Z; Ismail, Nasser S M.
Afiliação
  • Abd El-Sattar NEA; Department of Chemistry, Organic Labs, Computational Chemistry Lab, Faculty of Science, Ain Shams University Cairo 11566 Egypt nourel-dinahmed@sci.asu.edu.eg.
  • Badawy EHK; Department of Chemistry, Organic Labs, Computational Chemistry Lab, Faculty of Science, Ain Shams University Cairo 11566 Egypt nourel-dinahmed@sci.asu.edu.eg.
  • Elrazaz EZ; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University Abbassia 11566 Cairo Egypt eman_elrazaz@pharma.asu.edu.eg.
  • Ismail NSM; Pharmaceutical Chemistry Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt (FUE) Cairo 12311 Egypt.
RSC Adv ; 11(8): 4454-4464, 2021 Jan 21.
Article em En | MEDLINE | ID: mdl-35424391
ABSTRACT
Poly(ADP-ribose) polymerases-1 (PARP-1) are involved in DNA repair damage and so PARP-1 inhibitors have been used as potentiators in combination with DNA damaging cytotoxic agents to compromise the cancer cell DNA repair mechanism, resulting in genomic dysfunction and cell death. In this study, we report the synthesis of a novel series of pyrano[2,3-d]pyrimidine-2,4-dione analogues as potential inhibitors against PARP-1. All the newly synthesized compounds were evaluated for their inhibitory activity towards PARP-1 and examined for their anti-proliferative activity against MCF-7 and HCT116 human cancer cell lines. The synthesized compounds showed promising activity where compounds S2 and S7 emerged as the most potent PARP-1 inhibitors with an IC50 value of 4.06 ± 0.18 and 3.61 ± 0.15 nM, respectively compared to that of Olaparib 5.77 nM and high cytotoxicity against MCF-7 with IC50 2.65 ± 0.05 and 1.28 ± 1.12 µM, respectively (Staurosporine 7.258 µM). Compound S8 remarkably showed the highest cell growth inhibition against MCF-7 and HCT116 with an IC50 value of 0.66 ± 0.05 and 2.76 ± 0.06 µM, respectively. Furthermore, molecular docking of the compounds into the PARP-1 active site was performed to explore the probable binding mode. Finally, most of the synthesized compounds were predicted to have good pharmacokinetics properties in a theoretical kinetic study.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article